Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Pharmacologic Substance > Phosphodiesterase 5 Inhibitor

Phosphodiesterase 5 Inhibitor

Phosphodiesterase 5 Inhibitors are a class of compounds that block the action of the enzyme phosphodiesterase 5, which is involved in the regulation of cyclic guanosine monophosphate (cGMP) levels.
These inhibitors have been studied for their potential therapeutic applications, particularly in the treatment of erectile dysfunction, pulmonary hypertension, and other conditions related to vascular function.
Researchers can use PubCompare.ai's AI-driven protocol comparisons to easily identify the most effective methods and products for Phosphodiesterase 5 Inhibitor research, boosting their productivity and experincing the future of this important field.

Most cited protocols related to «Phosphodiesterase 5 Inhibitor»

1
Defining Erectile Dysfunction in Epidemiological Studies
Cited 5 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2016
Coitus Hypersensitivity Males Penile Erection Phosphodiesterase 5 Inhibitor
2
Chronic Kidney Disease and Associated Conditions
Cited 3 times
Expanded definition of chronic kidney disease (to include general practitioner recorded diagnosis of chronic kidney disease stage 3 in addition to stages 4 and 5 as well as major chronic renal disease)
Measure of systolic blood pressure variability (standard deviation of repeated measures)
Diagnosis of migraine (including classic migraine, atypical migraine, abdominal migraine, cluster headaches, basilar migraine, hemiplegic migraine, and migraine with or without aura)
Corticosteroid use (British National Formulary (BNF) chapter 6.3.2 including oral or parenteral prednisolone, betamethasone, cortisone, depo-medrone, dexamethasone, deflazacort, efcortesol, hydrocortisone, methylprednisolone, or triamcinolone)
Systemic lupus erythematosus (including diagnosis of SLE, disseminated lupus erythematosus, or Libman-Sacks disease)
Second generation “atypical” antipsychotic use (including amisulpride, aripiprazole, clozapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, sertindole, or zotepine)
Diagnosis of severe mental illness (including psychosis, schizophrenia, or bipolar affective disease)
Diagnosis of HIV or AIDS
Diagnosis of erectile dysfunction or treatment for erectile dysfunction (BNF chapter 7.4.5 including alprostadil, phosphodiesterase type 5 inhibitors, papaverine, or phentolamine)
Hippisley-Cox J., Coupland C, & Brindle P. (2017). Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. The BMJ, 357, j2099.
Full text: Click here
Publication 2017
Abdominal Migraine Adrenal Cortex Hormones Alprostadil Amisulpride Antipsychotic Agents Aripiprazole Basilar-Type Migraine Betamethasone Bipolar Disorder Chronic Kidney Diseases Clozapine Cluster Headache Common Migraine Cortisone deflazacort Depo-Medrone Dexamethasone Diagnosis Erectile Dysfunction Hydrocortisone Libman-Sacks Disease Lupus Erythematosus, Systemic Lurasidone Mental Disorders Methylprednisolone Migraine Disorders Migraine with Aura Olanzapine Paliperidone Papaverine Parenteral Nutrition Phentolamine Phosphodiesterase 5 Inhibitor Prednisolone Psychotic Disorders Quetiapine Risperidone Schizophrenia sertindole Systolic Pressure Triamcinolone zotepine
3
CTEPH Management Protocol for High-Risk Patients
Cited 2 times
We selected patients with CTEPH (age 20–85 years) as confirmed by a pulmonary ventilation/perfusion scan, pulmonary angiography and a chest computed tomography scan, two or more of which revealed areas of deficient pulmonary blood flow. Pulmonary haemodynamic variables at rest, as determined by right heart catheterisation, were set as the baseline. The mean pulmonary arterial pressure (mPAP) was set at ≥25 mmHg; the pulmonary artery wedge pressure (PAWP) was set at ≤15 mmHg; and PVR was set at >360 dyn·s·cm−5. The population consisted of patients who could not undergo PEA due to the presence of organised peripheral thrombus. This study also included patients who could not undergo PEA due to their high risk (e.g. comorbidities or old age), or for other reasons (e.g. refusal to undergo surgery). These disease classifications were assessed by each investigator at their own institution. The population also consisted of some patients who had persistent or recurrent PH after PEA or BPA.
Those who had received prostacyclin and/or its derivatives were excluded. Concomitant use of riociguat, an endothelin receptor antagonist (ERA), a phosphodiesterase-5 inhibitor or a calcium antagonist was allowed if the doses administered had been stable for ≥90 days before the baseline right heart catheterisation and it was maintained until the end of this double-blind study. While patients who had undergone PEA and/or BPA were included, PEA and BPA were not allowed during the study. Details of the inclusion and exclusion criteria are provided in the supplementary material.
This study was conducted in accordance with the ethical principles set out by the institutional human ethics committees of the participating facilities or regions and the Declaration of Helsinki. The study design was approved by the institutional review board at each study site, including the National Cerebral and Cardiovascular Centre (reference number #924). All subjects provided written informed consent to participate in the study.
Ogo T., Shimokawahara H., Kinoshita H., Sakao S., Abe K., Matoba S., Motoki H., Takama N., Ako J., Ikeda Y., Joho S., Maki H., Saeki T., Sugano T., Tsujino I., Yoshioka K., Shiota N., Tanaka S., Yamamoto C., Tanabe N, & Tatsumi K. (2022). Selexipag for the treatment of chronic thromboembolic pulmonary hypertension. The European Respiratory Journal, 60(1), 2101694.
Publication 2022
Angiography Calcium Channel Blockers Cardiovascular System Catheterizations, Cardiac Chest derivatives Endothelin Receptor Antagonist Epoprostenol Ethics Committees, Research Hemodynamics Homo sapiens Institutional Ethics Committees Lung Operative Surgical Procedures Patients Phosphodiesterase 5 Inhibitor Pulmonary Circulation Pulmonary Wedge Pressure Radionuclide Imaging riociguat Thrombus Ventilation-Perfusion Scan X-Ray Computed Tomography
4
PKG1α and TSC2 Regulation of Cardiomyocyte Signaling
Cited 2 times
NRCMs were freshly isolated and incubated with plasmid or adenovirus vectors prepared to express either WT or CS/CS forms of PKG1α, and/or WT, S1365E (phospho-mimetic), or S1365A (phospho-null) forms of TSC2, as described7 (link), 17 (link). After 24–36 hours in culture, transfected cells were stimulated with endothelin-1 (ET-1, 10 nM, Sigma, for 15 min or 48 hours depending on the experiment) or with vehicle in serum-free DMEM media supplemented with 0.1% Insulin-Transferrin-Selenium (Life Technologies). In some studies, cells were also exposed to the PKG1α inhibitor (DT3, 1 μM), PDE9 inhibitor (PF-04447943, 10 μM), PDE5 inhibitor (sildenafil, 1 μM), GC-1 activator (BAY-602770, 0.1 μM), or vehicle to test the role of kinase activation. PKG1 activators were tested against a mTORC1 inhibitor (everolimus, 1 μM) or vehicle. In other studies, myocytes were infected with an adenovirus expressing a tandem fluorescent LC3 reporter (Ad-TF-LC3) (gift of Dr. Junichi Sadoshima)7 (link).
Oeing C.U., Nakamura T., Pan S., Mishra S., Dunkerly-Eyring B.L., Kokkonen-Simon K.M., Lin B.L., Chen A., Zhu G., Bedja D., Lee D.I., Kass D.A, & Ranek M.J. (2020). PKG1α Cysteine-42 Redox State Controls mTORC1 Activation in Pathological Cardiac Hypertrophy. Circulation research, 127(4), 522-533.
Publication 2020
Adenovirus Vaccine Cells cGMP-Dependent Protein Kinase Ialpha Cloning Vectors Culture Media, Serum-Free Endothelin-1 Everolimus Insulin Mechanistic Target of Rapamycin Complex 1 Muscle Cells PF-04447943 Phosphodiesterase 5 Inhibitor Phosphotransferases Plasmids Selenium Sildenafil Transferrin Tuberous Sclerosis 2
5
Feasibility of Precision Prostatectomy
Cited 2 times
We examined the feasibility of precision prostatectomy in eight carefully selected men who were desirous of focal therapy to the prostate (IDEAL stage 1/2a). These men were evaluated and treated over a 6-month period, between January and July 2017, allowing a minimum follow-up of 24 months. All men placed high priority on preservation of erectile function and sought out the treating surgeon specifically requesting focal therapy. No man was a candidate for active surveillance, and all met the following criteria: (1) PSA ≤15 ng/mL, (2) stage ≤cT2, (3) dominant unilateral lesion with Gleason score ≤4+3 with any number of cores or % cores involved ipsilaterally on TRUS prostate biopsy, (4) no primary Gleason score ≥4 contralaterally on TRUS prostate biopsy, and (5) preoperatively potent without phosphodiesterase type 5 (PDE-5) inhibitors. Data collection was under an ongoing protocol approved by the Institutional Review Board, and in compliance with Health Insurance Portability and Accountability Act of 1996 (HIPAA) regulations. Informed consent was obtained from all patients. The patients were apprised of the experimental nature of the procedure, and the fact that the risks could not be accurately estimated given the novelty of the procedure. Patients were required to review the informational material for at least 7 days before they were considered for precision prostatectomy. Failing this in-home evaluation, patients were assigned to conventional radical prostatectomy.
Patient positioning, port placement, developing the space of Retzius and prostatic pedicle dissection followed our standard anterior Vattikuti Urology Institute technique of prostatectomy.19 20 (link) However, in the precision prostatectomy, standard nerve-sparing radical prostatectomy was undertaken on the side of the dominant lesion. On the contralateral side, the dissection was started anterior to the vas deferens/seminal vesicle complex, preserving all layers of Denonvilliers' fascia, with the included erectogenic nerves.21 22 (link) The dissection was continued 5–10 mm into the prostatic capsule, deliberately attempting to leave behind a thin rim of prostatic capsule (5–10 mm) along with the seminal vesicle/ejaculatory duct complex. Systematic needle biopsies (via a suprapubic approach) were taken from the remnant prostatic tissue, and sent for frozen section analysis. Completion prostatectomy was performed if the frozen biopsies showed residual cancer. Vesicourethral anastomosis was performed as previously described.19 20 (link) The patients received a Foley or suprapubic tube per patient choice.
For the stage 1/2a study, our goals were to assess:
Sood A., Jeong W., Taneja K., Abdollah F., Palma-Zamora I., Arora S., Gupta N, & Menon M. (2019). The Precision Prostatectomy: an IDEAL Stage 0, 1 and 2a Study. BMJ Surgery, Interventions, & Health Technologies, 1(1), e000002.
Publication 2019
Biologic Preservation Biopsy Capsule Cryoultramicrotomy Dissection Ductus Deferens Ejaculatory Ducts Ethics Committees, Research Fascia Freezing Ideal 1 Needle Biopsies Nervousness Patients Penile Erection Phosphodiesterase 5 Inhibitor Prostate Prostatectomy Residual Cancer Seminal Vesicles Surgeons Surgical Anastomoses Therapeutics Tissues

Most recents protocols related to «Phosphodiesterase 5 Inhibitor»

1
Comprehensive Evaluation of Erectile Function
A detailed examination of all participants’ medical histories was conducted and consisted of the following:
All enrollees underwent a comprehensive reproductive system examination to assess testicular and penile development. The erectile function of all participants was assessed with the 5-item International Index of Erectile Function (IIEF-5).24 (link) Scores between 22 and 25 were assessed as non-ED, 17 to 21 as mild, 12 to 16 as mild to moderate, 8 to 11 as moderate, and 1 to 7 as severe ED.25 (link) We used the audiovisual sexual stimulation and RigiScan test with oral phosphodiesterase 5 inhibitors to assess penile rigidity and tumescence to preliminarily screen for and rule out psychogenic ED. The definition of a typical result is based on the Chinese population criteria proposed by basal stiffness >60% sustained ≥8.75 min, average event stiffness of tip ≥43.5% and base ≥50.5%, and average maximum stiffness of tip ≥62.5% and base ≥67.5%.26 (link)
Venous blood samples were collected from all participants between 8 am and 10 am after a 12-hour overnight fast to measure fasting blood glucose, total cholesterol, total triglycerides, B12, HCY, FA, and Hp-IgG titer. Serum B12, FA, and HCY levels were determined by chemiluminescence immunoassay (ADVIA Centaur XP; Siemens Medical Diagnostics). Hp-IgG titers were quantified by enzyme-linked immunosorbent assay with commercially available kits (Abnova), following the manufacturer’s guidelines.
Xu J., Xu Z., Pan H, & Zhou Z. (2023). Association between erectile dysfunction and Helicobacter pylori, folic acid, vitamin B12, and homocysteine: a cross-sectional study. Sexual Medicine, 11(2), qfac018.
Full text: Click here
Publication 2023
Blood Glucose Chemiluminescent Assays Chinese Cholesterol Diagnosis Enzyme-Linked Immunosorbent Assay Genitalia Muscle Rigidity Penile Erection Penis Phosphodiesterase 5 Inhibitor Serum Testis Triglycerides Veins
2
Evaluating Reliable TikTok Videos on PE
The TikTok videos were classified as reliable if they contained medically accurate information about the disease and/or options for treatment. Medically correct information about PE included, as per the American Urological Association (AUA), the definition, indications for treatment, and/or epidemiological factors. To be considered valid, definitions for PE had to specifically included mention of any of the 3 components of PE: short latency period, lack of control of ejaculation, and clinically significant bother associated with ejaculation. Reliable AUA-recommended treatment options included psychological/behavioral strategies (such as the stop and start program, squeeze technique, or sensate focus masturbation before sexual intercourse), pharmacological options (including dapoxetine, other off-label antidepressants, topical anesthetic agents, tramadol, phosphodiesterase-5 inhibitor [PDE5i], or combination treatments) or other scientifically proven methods (acupuncture or modanafil).
Bernstein A., Zhu M., Loloi J., Babar M., Winokur N., Wysocki M, & Cohen S. (2023). TikTok as a source of information regarding premature ejaculation: a qualitative assessment. Sexual Medicine, 11(2), qfac020.
Full text: Click here
Publication 2023
Antidepressive Agents Coitus dapoxetine Ejaculation Phosphodiesterase 5 Inhibitor Therapy, Acupuncture Topical Anesthetics Tramadol
3
Mpox Surveillance in Urban Clinics
The following data were extracted for each participant: MVA-BN vaccination, mpox diagnosis, RT–PCR laboratory results, age, geographical district of primary healthcare clinic, population sector, the score for socioeconomic status, history of HIV/AIDS; STIs detected in rectal, pharyngeal or urine PCR tests; blood test for syphilis screening (TPHA) and dispense of HIV-PrEP therapy and PDE5 inhibitors (sildenafil, tadalafil or vardenafil).
The CHS data repositories and the definition of the sociodemographic variables were previously described in published coronavirus disease 2019 studies22 (link). Data were extracted on 29 December 2022.
Wolff Sagy Y., Zucker R., Hammerman A., Markovits H., Arieh N.G., Abu Ahmad W., Battat E., Ramot N., Carmeli G., Mark-Amir A., Wagner-Kolasko G., Duskin-Bitan H., Yaron S., Peretz A., Arbel R., Lavie G, & Netzer D. (2023). Real-world effectiveness of a single dose of mpox vaccine in males. Nature Medicine, 29(3), 748-752.
Publication 2023
3-(2-methoxyphenyl)-5-methoxy-1,3,4-oxadiazol-2(3H)-one Acquired Immunodeficiency Syndrome BLOOD COVID 19 Diagnosis Hematologic Tests MVA vaccine Pharynx Phosphodiesterase 5 Inhibitor Primary Health Care Rectum Reverse Transcriptase Polymerase Chain Reaction Sexually Transmitted Diseases Sildenafil Syphilis Syphilis Serodiagnosis Tadalafil Therapeutics Urinalysis Vardenafil
4
COVID-19 and Erectile Dysfunction
This study was initiated after obtaining approval from the Clinical Research Ethics Committee of Health Sciences University Diskapi Yıldırım Beyazıt Training and Research Hospital affiliated with the Republic of Turkey Ministry of Health (approval date: 13 December 2021, number: 126/22). A total of 125 healthy male healthcare workers, 95 with and 30 without a history of COVID-19, were evaluated in terms of erectile function. The inclusion criteria were being aged 30–50 years, having been treated for COVID-19, being married or in a regular sexual relationship, and having had a regular income since the beginning of the pandemic. Excluded from the study were individuals who had received COVID-19 treatment in a hospital or intensive care unit, those with a history of cardiopulmonary involvement, those using phosphodiesterase-5 inhibitors/androgen replacement drugs/5-alpha-reductase inhibitors, and those with a diagnosis of psychiatric disease/diabetes mellitus/hypertension/erectile dysfunction. In order to evaluate the erectile function of the participants, they were asked to complete the five-item International Index of Erectile Function (IIEF-5). The total score in this questionnaire varies between 5 and 25 and classified as follows: 22–25, no ED; 17–21, mild ED, 12–16; mild to moderate ED; 8–11, moderate ED, and 5–7, severe ED. Four study groups were formed. The first three groups consisted of individuals who had a history of COVID-19 confirmed by the polymerase chain reaction (PCR) test at different times and recovered from the disease. Group 4 constituted the control group without a history of COVID-19 diagnosis. The details of the study groups are given below.

Group 1 (n = 30): COVID-19 PCR positivity within the past 6 months;

Group 2 (n = 31): COVID-19 PCR positivity 6 to 12 months before the study period;

Group 3 (n = 34): COVID-19 PCR positivity longer 12 months before the study period;

Group 4 (n = 30): No COVID-19 history.

Gök A., Altan M., Doğan A.E., Eraslan A., Uysal F.Ş., Öztürk U., Saguner A.M, & İmamoğlu M.A. (2023). Does Post-COVID-19 Erectile Dysfunction Improve over Time?. Journal of Clinical Medicine, 12(3), 1241.
Full text: Click here
Publication 2023
Androgens COVID 19 Diabetes Mellitus Diagnosis Diagnosis, Psychiatric Erectile Dysfunction Ethics Committees, Clinical Health Personnel High Blood Pressures Hospital Administration Males Oxidoreductase Pandemics Penile Erection Pharmaceutical Preparations Phosphodiesterase 5 Inhibitor Polymerase Chain Reaction
5
Comprehensive Search for Pulmonary Hypertension Therapies
A comprehensive literature search was performed in electronic databases, including PubMed/Medline, Embase, Web of Science, Open Grey and Google Scholar, from January 1, 2013, to December 31, 2021. The language was limited to English. The search keywords were “pulmonary arterial hypertension”, “Adempas”, “riociguat”, “BAY 63-2521”, “tadalafil”, “sildenafil” and “phosphodiesterase-5 inhibitors”. The refined search formula was ((pulmonary hypertension [Title/Abstract]) AND (therapy [Title/Abstract])) AND ((tadalafil [Title/Abstract]) OR (sildenafil [Title/Abstract]) OR (phosphodiesterase-5 inhibitors [Title/Abstract])) AND ((Adempas [Title/Abstract]) OR (Riociguat[Title/Abstract])). References of all relevant studies were further reviewed by two reviewers to ensure that all relevant studies were identified.
Liu Y.Y., Qu Y.Y., Wang S., Luo C.J., Qiu H.L., Li H.T., Yuan P., Wang L., Li J.L., Jiang R, & Zhang R. (2023). Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis. Frontiers in Pharmacology, 14, 1052546.
Full text: Click here
Publication 2023
Adempas BAY 63-2521 Idiopathic Pulmonary Arterial Hypertension Phosphodiesterase 5 Inhibitor Pulmonary Hypertension riociguat Sildenafil Tadalafil Therapeutics

Top products related to «Phosphodiesterase 5 Inhibitor»

1
Sildenafil by Merck Group
Sourced in United States, Germany, China, United Kingdom
Sildenafil is a laboratory product manufactured by Merck Group. It is a chemical compound used in various research and development applications. The core function of Sildenafil is to serve as a research tool for scientific investigations, without any extrapolation on its intended use.
2
Bovine serum albumin (bsa) by Merck Group
Sourced in United States, Germany, United Kingdom, China, Italy, Japan, France, Sao Tome and Principe, Canada, Macao, Spain, Switzerland, Australia, India, Israel, Belgium, Poland, Sweden, Denmark, Ireland, Hungary, Netherlands, Czechia, Brazil, Austria, Singapore, Portugal, Panama, Chile, Senegal, Morocco, Slovenia, New Zealand, Finland, Thailand, Uruguay, Argentina, Saudi Arabia, Romania, Greece, Mexico
Bovine serum albumin (BSA) is a common laboratory reagent derived from bovine blood plasma. It is a protein that serves as a stabilizer and blocking agent in various biochemical and immunological applications. BSA is widely used to maintain the activity and solubility of enzymes, proteins, and other biomolecules in experimental settings.
3
Trypsin by Merck Group
Sourced in United States, Germany, United Kingdom, China, Italy, Japan, Sao Tome and Principe, Canada, Macao, Poland, India, France, Spain, Portugal, Australia, Switzerland, Ireland, Belgium, Sweden, Israel, Brazil, Czechia, Denmark, Austria
Trypsin is a serine protease enzyme that is commonly used in cell biology and biochemistry laboratories. Its primary function is to facilitate the dissociation and disaggregation of adherent cells, allowing for the passive release of cells from a surface or substrate. Trypsin is widely utilized in various cell culture applications, such as subculturing and passaging of adherent cell lines.
4
Tadalafil by Selleck Chemicals
Sourced in United States
Tadalafil is a white to off-white crystalline solid that is practically insoluble in water. It is a phosphodiesterase type 5 (PDE5) inhibitor. Tadalafil is used as a reference standard in analytical procedures.
5
Trizol rna isolation reagent by Thermo Fisher Scientific
Sourced in United States, Japan, United Kingdom, China, Germany, France
TRIzol is a ready-to-use reagent for the isolation of total RNA from a variety of biological samples. It is a monophasic solution of phenol, guanidine isothiocyanate, and other proprietary components that facilitate the extraction and purification of RNA.
6
Plastic ware for cell cultures by Corning
Sourced in Italy
Corning's plastic ware for cell cultures is designed to provide a controlled and sterile environment for the growth and maintenance of cells. These products include culture dishes, flasks, and plates made of high-quality, durable plastic materials. They are engineered to support the specific requirements of cell culture applications.
7
Disposable filtration units for growth media preparation by Corning
Sourced in Italy
Disposable filtration units for growth media preparation. These units are designed to filter growth media, removing unwanted particulates and contaminants.
8
Sildenafil by Pfizer
Sourced in United States, China
Sildenafil is a laboratory product used for research and scientific analysis. It is a chemical compound that can be used in various experimental and analytical applications. The core function of Sildenafil is to serve as a tool for researchers and scientists, without any interpretation or extrapolation on its intended use.
9
Rolipram by Merck Group
Sourced in United States, Germany, United Kingdom, Switzerland
Rolipram is a laboratory equipment product manufactured by Merck Group. It is a selective inhibitor of the phosphodiesterase-4 (PDE4) enzyme. Rolipram is used in research and scientific applications to study the effects of PDE4 inhibition.
10
Dntp mix by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, Japan, Canada, France, China, Belgium, Sweden, India
The DNTP mix is a solution containing a balanced combination of the four deoxyribonucleotide triphosphates (dATP, dCTP, dGTP, and dTTP) commonly used in various molecular biology applications such as DNA amplification, sequencing, and synthesis.

More about "Phosphodiesterase 5 Inhibitor"

Phosphodiesterase 5 (PDE5) Inhibitors are a class of compounds that block the action of the enzyme PDE5, which regulates cyclic guanosine monophosphate (cGMP) levels.
These inhibitors have been extensively studied for their potential therapeutic applications, particularly in the treatment of erectile dysfunction, pulmonary hypertension, and other conditions related to vascular function.
Sildenafil, a well-known PDE5 inhibitor, is commonly used for the treatment of erectile dysfunction.
Bovine serum albumin (BSA) and trypsin are often used in cell culture and protein purification processes related to PDE5 research.
Tadalafil is another PDE5 inhibitor that has been approved for the treatment of erectile dysfunction and pulmonary arterial hypertension.
The TRIzol RNA isolation reagent can be utilized to extract and purify RNA samples for gene expression studies related to PDE5.
Plastic ware for cell cultures and disposable filtration units for growth media preparation are essential tools in PDE5 inhibitor research.
Rolipram, a phosphodiesterase-4 (PDE4) inhibitor, has also been investigated for its potential therapeutic effects, as PDE4 is involved in the regulation of inflammatory processes.
Researchers can leverage PubCompare.ai's AI-driven protocol comparisons to easily identify the most effective methods and products for Phosphodiesterase 5 Inhibitor research, boosting their productivity and experiencing the future of this important field.
The platform's comprehensive database of literature, pre-prints, and patents can help researchers stay up-to-date with the latest advancements in PDE5 inhibitor research and development.